AstraZeneca merger talk with Bristol-Myers Squibb - $400 billion
A rumour that did not translate into a deal, but still moved prices.
A reported merger talk did not take place. According to Reuters, two people indicated there was no active merger discussion. AstraZeneca (AZN) recovered partially on the "no deal" update (Aug 05: 2.9%+ intraday) but remained 6.2% below pre-news levels at 11,850p as of Aug 06.
Bristol-Myers Squibb (BMY) fell 2.6% on the "no deal" news (Aug 05), consistent with investors having positioned for a takeover premium. BMY closed at US$64.15 on Aug 06 and was 1.8% below pre-news levels.
Bristol-Myers Squibb is nearly half the size of AstraZeneca, carries52% more debt, but produces higher free cash flow. A common large-cap acquisition convention is a ~30% premium, which would imply a BMY price of about US$83.40 from US$64.15.
Company snapshot
| Stats | AstraZeneca (AZN) | Bristol-Myers Squibb (BMY) |
|---|---|---|
| Latest Close (Aug 06) | 11,850p | US$64.15 |
| Market Cap | US$ 247.50 billion | US$ 131.04 billion |
| Enterprise Value | US$ 274.85 billion | US$ 163.09 billion |
| Cash (FY2025) | US$ 5.71 billion | US$ 10.21 billion |
| Total Debt (FY2025) | US$ 29.62 billion | US$ 45.11 billion |
| Free Cash Flow (FY2025) | US$ 8.96 billion | US$ 12.84 billion |
Pricing reaction and figures as presented in the provided brief.
Source note
Reuters was referenced for the "no deal" confirmation. Market figures are directional and shown for context.
Author: Strategyland Research Team